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Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are a major 
burden to patients and to society. Little is known about the possible role of day-to-day patient-
reported outcomes during an exacerbation. This study aims to describe the day-to-day course of 
patient-reported health status during exacerbations of COPD and to assess its value in predicting 
clinical outcomes.
Methods: Data from two randomized controlled COPD exacerbation trials (n = 210 and n = 
45 patients) were used to describe both the feasibility of daily collection of and the day-to-day 
course of patient-reported outcomes during outpatient treatment or admission to hospital. In 
addition to clinical parameters, the BORG dyspnea score, the Clinical COPD Questionnaire 
(CCQ), and the St George’s Respiratory Questionnaire were used in Cox regression models to 
predict treatment failure, time to next exacerbation, and mortality in the hospital study.
Results: All patient-reported outcomes showed a distinct pattern of improvement. In the mul-
tivariate models, absence of improvement in CCQ symptom score and impaired lung function 
were independent predictors of treatment failure. Health status and gender predicted time to next 
exacerbation. Five-year mortality was predicted by age, forced expiratory flow in one second % 
predicted, smoking status, and CCQ score. In outpatient management of exacerbations, health 
status was found to be less impaired than in hospitalized patients, while the rate and pattern of 
recovery was remarkably similar.
Conclusion: Daily health status measurements were found to predict treatment failure, which 
could help decision-making for patients hospitalized due to an exacerbation of COPD.
Keywords: health status, Clinical COPD Questionnaire, hospital, admission, prediction
Introduction
Exacerbations in patients with chronic obstructive pulmonary disease (COPD) are 
known to be associated with high inhospital mortality as well as in the following years.1,2 
The number of exacerbations strongly influences mortality.3 Other consequences of 
a higher frequency of exacerbations are high socioeconomic cost,4 deterioration in 
quality of life,5–8 and increased decline in lung function.9
The definition and management of exacerbations of COPD remains a challenge. 
Diagnosis of an exacerbation is based exclusively on clinical parameters that have an 
important day-to-day variation.10 However, because the way clinicians interpret clinical 
information varies, the clinical decisions may also vary.11,12 To facilitate decision-
making, models have been developed that predict outcome in exacerbations of COPD 
at the emergency department and the intensive care unit.13,14 Some of these models also 
use patient-reported outcomes, ie, the modified Medical Research Council scale for 
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the “usual” severity of dyspnea.15 Health status/health-related 
quality of life, an important patient-reported outcome, has 
not been included in current models even though health-
related quality of life measurements at first consultation 
for an exacerbation may yield important information for 
stratification of the patients.16 Recently updated Global initia-
tive for chronic Obstructive Lung Disease (GOLD) guidelines 
have for the first time divided patients diagnosed with COPD 
into categories based on annual number of exacerbations, 
GOLD stage, Medical Research Council and health status 
as assessed with the COPD Assessment Test (CAT) or the 
Clinical COPD Questionnaire (CCQ).10 However, the role 
of evaluation of health status in assessing and managing 
exacerbations has been limited so far to follow-up visits after 
discharge from hospital.10
New treatment paradigms in COPD are proposed, shift-
ing from best current control only to incorporate future 
risk estimation and reduction.17 Patient-reported outcomes 
as assessed with health-related quality of life tools may be 
used to guide treatment in COPD, especially if they can 
be proven to predict future events. This would require simple 
and easy to complete health status questionnaires, such as 
the CCQ.18,19
The present study evaluates the feasibility of daily patient-
reported outcome measurements during exacerbations 
either treated at home or in hospital, describes the course of 
patient-reported outcomes during exacerbations, and assesses 
whether patient reported-outcomes on the CCQ, St George’s 
Respiratory Questionnaire (SGRQ), and BORG scale could 
help decision-making in exacerbation of COPD. It also 




The present study used data from two randomized clinical 
trials. Study one was a randomized, double-blind, double-
dummy, placebo-controlled clinical trial assessing the 
noninferiority of oral and intravenous corticosteroids during 
hospitalization because of an exacerbation of COPD, labeled 
the inhospital study.20 Study two was a randomized, double-
blind, placebo-controlled clinical trial evaluating the effects 
of 14 days of combined high-dose budesonide/formoterol, 
prednisolone, or placebo during an exacerbation of COPD in 
an outpatient setting, labeled the outpatient study.21
In both trials, an exacerbation of COPD was defined as a 
history of increased breathlessness and the presence of at least 
two of the following symptoms for at least 24 hours: increased 
cough frequency or severity; increased sputum volume or 
purulence; and increased wheeze. In both trials, therapy has 
started immediately after an exacerbation was recorded. In 
the inhospital study, patients hospitalized for an exacerbation 
of COPD received either oral or intravenous prednisolone 
(double-dummy) for five days followed by tapering of the 
dosage using oral prednisolone.20 The primary endpoint was 
treatment failure, defined as all-cause mortality, intensive care 
unit admission, intensification of pharmacological treatment, 
or rehospitalization within 14 days (early treatment failure) or 
90 days (late treatment failure). Excluded were patients with 
signs of a very severe exacerbation on admission (arterial 
pH , 7.26 or PaCO
2
 . 9.3 kPa), those with significant or 
instable comorbidity, and those with a history of asthma.
To assess exacerbations and survival status, hospital and 
general practitioner records were reviewed as an extension 
of the initial study. The second outpatient study evaluated the 
effects of 14 days of combined high-dose inhaled budesonide/
formoterol, oral prednisolone, or placebo (double-dummy) 
during an exacerbation of COPD.21 Patients were recruited, 
taken off inhaled steroids, and were randomized to one of the 
three treatment arms at the start of an exacerbation. Patients 
were treated at home. In this second study, we used their origi-
nal data to make assessments on health status and dyspnea but 
we did not have access to survival status data. Both studies 
were ethically approved and registered at  ClinicalTrials.gov 
(I:NCT00311961, II:NCT00239278).
Measurements
Lung function was measured according to American 
Thoracic Society/European Respiratory Society guidelines at 
admission, and on days 3, 5, and 7. An absolute difference of 
100 mL in forced expiratory flow in one second (FEV
1
) has 
been suggested to be clinically relevant.22  Arterial blood gases 
were obtained on the day of admission, and on days 2, 3, 5, 
and 7 (inhospital study). C-reactive protein and erythrocyte 
sedimentation rate were measured on admission. Lung 
function was assessed twice during the run-in period in the 
outpatient study and on days 1, 7, and 14 of the  inhospital 
study.
Patient-reported outcomes
All tests have measurement uncertainties, and small changes 
in results might not be clinically meaningful. For many tests, 
the cut-off for clinically meaningful changes is the minimal 
clinically important difference (MCID). The MCID helps 
to interpret changes in scores and can be used to assess the 
percentage of patients that benefit from an intervention.
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The BORG dyspnea score measures dyspnea on a scale 
from 0 (“nothing at all”) to 10 (“maximal”).23,24 The MCID 
for the BORG is 1 point.25 The BORG score was measured 
on days 1–5 and day 7 in the inhospital study.
The CCQ is a 10-item health status scale measuring 
symptoms, functional status, and mental state in patients 
with COPD. Scores range from 0 (best) to 6 (worst).18 The 
MCID is 0.4.26 The CCQ has a 24-hour and a one-week 
version. It was administered in hospital on days 1–5 and 7 
using the diary version and at six weeks using the standard 
week version. In the outpatient exacerbation study, the CCQ 
was administered similarly at baseline, two months after 
stopping inhaled corticosteroids, on the first exacerbation 
day, and on days 3, 7, and 14.
The SGRQ is a 50-question, 76-item health status scale 
for both asthma and COPD patients.27 The SGRQ has three 
subscales, ie, symptoms, activities, and impact. In the present 
study, the standard three-month version was used.27 The 
score ranges from 0 (best) to 100 (worst).20 The MCID is 
4 points.28 The standard SGRQ (three-month recall period) 
was administered on days 1 and 7.
Statistical analysis
Differences in patient characteristics between the two studies 
were tested by chi-square or independent t-tests. To compare 
the course of patient-reported outcomes and FEV
1
, all scores 
were normalized to the number of times the MCID. For 
example, a mean change in SGRQ score of 3 points resulted 
in a “number of MCID change” of (3 units/4 units = MCID) 
0.75. For the FEV
1
, an MCID of 100 mL was taken.22 We com-
puted this number of MCID changes in all patient-reported 
outcomes and FEV
1
 for each day during the hospitalization to 
represent the change graphically. To evaluate responsiveness, 
the number of patients that changed more than the MCID after 
seven days of treatment was calculated. Although the recall 
period is different in the patient-reported outcomes used, by 
standardization into the change in MCID, we have tried to 
reduce the influence of the different recall periods.
Cox regression models were used to assess predictors of 
treatment failure. Based on their clinical relevance and on 
the literature, the following variables were included in the 
univariate Cox models: treatment arm, age, gender,  smoking 
status, pack years, baseline FEV
1
% predicted, number of 
hospitalizations during the year prior to the exacerbation, 
long-term oxygen use, body mass index, SGRQ, and CCQ 
total and domain scores, BORG dyspnea score, blood gases, 
C-reactive protein, and erythrocyte sedimentation rate. 
Further, the change between day of admission and the next 
day for blood gases, BORG dyspnea score, and CCQ total 
and domain scores were also tested. Next, multivariate Cox 
regression models were used. In these models, treatment 
arm, FEV
1
% predicted, age, gender, smoking status, and 
all variables with a P value , 0.1 in the univariate model 
were entered. Because the CCQ, SGRQ, and BORG scores 
measure a similar construct, these were not entered in the 
models simultaneously, but their effects were estimated in 
three separate multivariate Cox models. Data were analyzed 
on an intention-to-treat basis. Statistical analyses were per-
formed using Statistical Package for Social Sciences version 
19 software (SPSS Inc, Chicago, IL, USA).
Results
The demographic characteristics of the patients with inhos-
pital and outpatient exacerbations are shown in Table 1. 
Patients who were admitted to hospital were generally older, 
had more severe airways obstruction, and had higher/worse 
CCQ scores (all P , 0.0001).
Feasibility
On the first day of hospital admission, 198 patients com-
pleted the BORG, 196 completed the CCQ, 197 completed 
the SGRQ, and 193 performed spirometry. Reasons for not 
completing the patient-reported outcomes were being too 
dyspneic to answer the questionnaires, not in the mood for 
completing questionnaires, not having reading glasses, or no 
clarified reason. There were no missing data in the outpatient 
group except for one patient for whom a CCQ was not 
recorded at the beginning of the exacerbation.
Table 1 Patient demographics
Hospital Outpatient
Patients (n) 210 45
Age, years 70.6 (8.4) 64.1 (8.1)
Male gender 158 (75.2) 37 (82.2)
FEV1% predicted 36.9 (14.73) 52.1 (12.9)
GOLD stage
 I 4 (2)
 II 33 (16.1) 26 (57.8)
 III 99 (48.3) 17 (37.8)
 IV 69 (33.7) 2 (4.4)
Pack-years (median [IQR]) 35 (24–50) 38 (26–48.5)
Current smokers 49 (23.7) 21 (46.7)
BORG score 4.6 (2.0) N/A
CCQ total score 3.3 (0.93) 2.6 (0.79)
SGRQ total score 63.1 (13.9) N/A
Note: Values are given as mean (standard deviation), or n (%). 
Abbreviations: FEV1, forced expiratory flow in one second; GOLD, The Global 
initiative for chronic Obstructive Lung Disease; CCQ, Clinical COPD Questionnaire; 
SGRQ, St George’s Respiratory Questionnaire; IQR, interquartile range.
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Course of patient-reported outcomes 
(dyspnea, health status, and domain 
scores)
Figure 1 shows the course of the FEV
1
, BORG, CCQ, and 
SGRQ total and domain scores in the inhospital study as 
assessed for each day within the first week. The FEV
1
 
improved only slightly (Figure 1A). The CCQ shows rapid 
improvement in total score on the first day, as well as in the 
functional, mental and symptoms domains, and continued to 
improve on the following days (Figure 1B). In the SGRQ, 
as in the CCQ, the domain measuring functional status, ie, 
the SGRQ activity domain and the CCQ functional state 
domain, were the most impaired. Scores on the symptom 
domains of both health status scales were less impaired, 
but still very high. The least impaired was the CCQ mental 
status domain and the SGRQ impact domain. However, 
23 patients still scored above 3 points on the CCQ mental 
state domain at admission and nine patients scored above 
3 points on day 7.
The BORG score for dyspnea decreased (improved) 
quickly during the first day of treatment in hospital, then 
stabilized (Figure 1C). Within the SGRQ, the activity and 
impact scores improved most (Figure 1D). To compare the 
course and responsiveness of the measurements, the abso-
lute mean scores were also shown normalized as number of 
MCIDs of the measurements (Figure 2).
The improvement between admission and day 7 repre-
sents the responsiveness of the FEV
1
and the patient-reported 
outcomes, and is expressed as mean change in absolute score, 
percentage change, and percentage of patients improving 
more than the MCID of the measurement (Table 2).
Course of CCQ on inhospital  
and outpatient treatment
The mean CCQ scores for the two study populations 
are shown in Figure 3.29 CCQ scores increased (deterio-
rated) significantly between stable status (before and after 























































































































































































Figure 1 Course of the mean FEV1, BORG, CCQ total and domain scores, and SGRQ total and domain scores. 
Abbreviations: FEV1, forced expiratory flow in one second; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; SGRQ, St George’s 
Respiratory Questionnaire.
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outpatient group. No data were available on pre-exacerbation 
CCQ in the hospital study because patients were enrolled 
during an exacerbation. The slope of the patients treated in 
hospital was −0.16 points/day in the first 7 days, while the 
mean change (ie, improvement) for the patients treated at 
home was −0.12 points/day. The rate of improvement did 
not differ significantly between the two groups.
Treatment failure
Thirty-eight of 210 patients admitted to hospital had early 
treatment failure, ie, within the first 14 days after admis-
sion. The models including patient-reported outcomes are 
shown in Table 3 and Table A1. In the models with the 
BORG or SGRQ score, the patient-reported outcome did 
not predict treatment failure. However, in the model with 
the CCQ, treatment failure was predicted by change in 
CCQ symptom score on the first day and FEV
1
% predicted 
on admission. To facilitate the decision rule for clini-
cians, we performed an additional analysis and calculated 
the hazard ratios (HR) for patients who did not improve 
in their symptoms as measured by the CCQ. A lack of 
improvement in CCQ symptom score in the first day of 
hospitalization had an HR of 2.6 (95% confidence interval 
[CI]: 1.2–5.8) and in that model the FEV
1
% predicted had 
an HR of 0.95 (95% CI: 0.91–0.99) in predicting time to 
treatment failure within 14 days after admission. All other 
clinical variables tested, including blood gases, were not 
predictive of time to treatment failure within 14 days, 
whether tested as continuous variables or dichotomously 
as normal or abnormal.
Time to re-exacerbation
Sixty-six percent of the 164 patients in whom complete 
data could be obtained from the hospital study had a re-
exacerbation within the first year, beginning at six weeks after 
hospitalization. Time to first re-exacerbation was predicted by 
CCQ total score at six weeks (HR 1.21, 95% CI: 1.01–1.46, 
Table A2). Patients in the highest tertile of the CCQ (.2.6) 
score had a hazard ratio of 1.88 (95% CI: 1.18–3.0) compared 
with the lowest tertile (CCQ , 1.8, Figure 4). Lung function, 
smoking status, age, GOLD stage, and SGRQ score did not 
predict time to re-exacerbation.
Mortality
The five-year mortality of the hospital-based study population 
was 54.9% with a median follow-up of 4.8 (interquartile 
range 4.2–5.2) years after initial admission. At day 42, 
the factors predicting increased all-cause mortality were age 
(HR 1.05, 1.02–1.08), a body mass index , 21 (HR 1.85, 
1.02–3.36) and CCQ score (HR 1.41, 1.18–1.69, Table A3). 
The SGRQ at day 42 after admission did not predict mortality 
(HR 1.01, 0.99–1.02), nor did the BORG dyspnea score. In 
the models with SGRQ and BORG, the FEV
1
% predicted 
became predictive for mortality, but not in the CCQ model. 
After adjusting for age, smoking status, gender, and FEV
1
% 









































































Figure 2 Mean change in minimal clinically important differences of FEV1, BORG, 
CCQ, and SGRQ.
Note: Error bars represent the standard error of measurement.
Abbreviations: FEV1, forced expiratory flow in one second; CCQ, Clinical COPD 
Questionnaire; COPD, chronic obstructive pulmonary disease; SGRQ, St George’s 
Respiratory Questionnaire; n, number of patients completed the measurement; 
MCID, minimal clinically important difference.
Table 2 Responsiveness of patient-reported outcomes and lung function on day 7
 n MCID Change score Change % from baseline ∆ . MCID % responders
BORG dyspnea 182 1 −1.76 (2.27) −32.2 (52.4) 72.1
CCQ hospital 181 0.4 −1.03 (1.04) −29.7 (31.2) 73.5
CCQ home 37 0.4 −0.71 (0.83) −26.2 (28.1) 59.5
SGRQ 179 4 −3.99 (13.23) −5.09 (22.8) 50.3
FEV1 (mL) hospital 179 100 mL 111 (9.0) 13.9 (10.1) 48.6
FEV1 (mL) home 45 100 mL 2.2 (17.8) 2.4 (11.3) 23.8
Notes: Values are presented as the mean (standard deviation). Change in patient-reported outcomes and lung function between admission and day 7, including the 
percentage of patients improving more than the MCID. 
Abbreviations: n, number of patients who completed the measurement on both admission and day 7; MCID, minimal clinically important difference; CCQ, Clinical COPD 
Questionnaire; SGRQ, St George’s Respiratory Questionnaire; FEV1, forced expiratory flow in one second.
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an HR for mortality of 3.10 (1.64–5.87) compared with the 
lowest CCQ tertile (Figure 5).
Discussion
In this study we demonstrated that daily measurement of 
patient-reported outcomes is feasible in patients experiencing 
an exacerbation of COPD. Health status measured by the CCQ 
predicted treatment failure and may therefore be useful in 
 decision-making. Further, CCQ scores measured six weeks after 
admission predicted time to re-exacerbation and mortality.
Feasibility
Most patients were able to complete the patient-reported 
outcomes, even at admission when their health was severely 
impaired. Patients completed the questionnaires themselves, 
assisted by the researchers only when needed; support was 
strictly limited to reading out the questions. SGRQ has been 
used as the gold standard for measurement of health status 
in clinical studies and exacerbation of COPD.5,30–32 However, 
exacerbation studies have assessed differences in health status 
over longer periods, from 1–6 months to 3 years.5,7,30.31 However, 
the length and complex scoring algorithm required for the 
SGRQ makes it less feasible in routine daily practice. During 
hospitalization, the SGRQ was administered twice within 
seven days, although seven days was too soon considering 
the recall period of the SGRQ which might have resulted in a 
smaller response in the symptoms domain. To be able to use the 
SGRQ during short follow-up studies, others have discarded its 
symptom domain.5 A total score should no longer be calculated 
without this domain, and as a result, the scores are no longer 

























































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Course of Clinical COPD Questionnaire total scores in hospitalized 
patients and outpatients during recovery from an exacerbation of COPD. 
Notes: Time points −2 and −1 represent run-in visits.
Reprinted with permission from Kocks JWH, Kerstjens HAM, van den Berg JWK, 
van der Molen T. The course of health status during an exacerbation of COPD 
in hospitalized patients versus outpatient treated patients. Prim Care Respir J. 
2010;19:A8–A9.29
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Course of patient-reported outcomes
The four measurements (FEV
1
, BORG, CCQ, and SGRQ) 
showed a different course of improvement during the 
first week of recovery, with the CCQ showing a profile in 
improvement similar to BORG dyspnea during home and 
hospital exacerbations. FEV
1
 improved by 13% compared 
with baseline, and almost 50% of patients improved above 
the MCID for FEV
1
.32,33 This improvement (111 mL) is more 
than previously described,32,33 but still not large. However, 
one needs to be aware that the suggested MCID is debated 
because the absolute number in mL is not related to age, 
gender, and height.
The BORG score showed the most improvement on the 
first day and remained fairly stable during the following 
days. In a similar study, Maltais et al found a change in score 
of 2.6 ± 2.3 points after three days of oral treatment with 
prednisolone, compared with 1.4 points within three days 
in our study.33
The CCQ total score improved by more than one MCID 
within the first day and continued to improve up to day 7, 
which is comparable with previous data.34 The SGRQ was 
measured only at admission and on day 7 and the mean score 
almost reached the MCID. However, the CCQ was more 
sensitive in assessing differences within days, given that it 
definitely reached the MCID from the first day.
Hospital versus outpatient health status 
scores
The health status of patients admitted to hospital during exac-
erbations was worse than that of those treated at home, which 
was expected because the decision for hospital admission is 
often made when patients present with more symptoms and 
more severe impairment of health status. The most important 
difference between the two groups was their health status 
and lung function on the first treatment day of treatment. 
However, both treatment groups showed a remarkably similar 
pattern in health status improvement. To our best knowledge, 
no other studies have shown a detailed course of change in 
health status during an exacerbation in COPD in both the 
hospital and outpatient settings, and that was the main reason 
we decided to present both study populations.
Domain scores in health status 
questionnaires
The domains that measure functional status, ie, the CCQ 
functional state domain and the SGRQ activity domains, 
were the most impaired. Next on the scale of impairment 
came the symptom domains. The fact that functional status 
domains were most impaired and the gradual recovery of the 
functional status domains as compared with breathlessness 
recorded by the BORG is interesting, because the recently 
developed Exacerbations of Chronic Pulmonary Disease 
Tool (EXACT) a patient-reported outcomes questionnaire, 
focuses on symptoms and not on functional status.35 Although 
symptom worsening is the key feature in exacerbations, 
limitations in functional status is what matters most to 
patients.36 The least impaired were the mental status domain 
and the SGRQ impact domain. However, 23 patients still 
scored above 3 points on the CCQ mental state domain at 
admission and nine patients scored above 3 points on day 7. 
A CCQ score above 3 is a strong predictor (odds ratio 15.17 
[3.19 –72.07]) for depressive symptoms assessed using the 
Hospital Anxiety and Depression Scale in primary care 
patients.37 This is an important finding because depression 
is associated with a worse outcome in patients with COPD, 
even affecting readmission to hospital.38 This advantage of 
the CCQ in containing different domains could be important 




















Figure 5 Proportion of patients alive after hospitalization for an exacerbation of 
COPD (CCQ score , 1.8; 1.8–2.6; .2.6). 











































Figure 4 Cox survival curve for re-exacerbation within a year, beginning at six 
weeks after hospitalization. 
Notes: Groups are divided by CCQ score tertiles (CCQ , 1.8; 1.8–2.6; . 2.6). 
Abbreviations: CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease.




Patient-reported outcomes and exacerbations of COPD
International Journal of COPD 2013:8
Most studies describe the course of symptoms alone 
during exacerbation and recovery,39–41 and in the event that 
health status is measured, generally it is evaluated at admis-
sion and after two weeks to three months.16 Health status 
provides more information than symptoms alone. In our 
study, dyspnea measured using the BORG score did not 
predict treatment failure, whereas SGRQ impact scores did 
in the univariate analysis. Although dyspnea improved rap-
idly after initiation of treatment, which is in accordance with 
other studies,42,43 improvement in dyspnea did not predict 
which patients would face treatment failure. On the other 
hand, in the model using the CCQ, treatment failure was 
predicted by a change in CCQ symptom score on the first day. 
Therefore, the CCQ is a useful tool for predicting treatment 
failure because it has the additional advantage of providing 
information not only on (dyspnea) symptom score but also 
on functional and mental state.
Treatment failure
Treatment failure in our study was predicted by a range of 





 and acidosis at admission, SGRQ 
total and impact score, and CCQ changes within one day. 
Several non-patient-reported outcomes have been reported 
as predictors of inhospital mortality or treatment failure.44,45 
Additional factors reported in the literature are gender, 
physical activity, Medical Research Council dyspnea score, 
O
2
 oxygen tension, body mass index, neurological impair-
ment, and use of inspiratory accessory muscles.14 Many of 
these studies report different predictors, probably because 
of use of different populations, measurements, and analyses; 
however, none of these studies have reported use of daily 
measurement of health status. In our multivariate models, 
only the FEV
1
% predicted and change in CCQ symptom 
score were significant independent predictors. Health status 
measurement with the CCQ is a useful candidate because it 
is feasible and inexpensive.
Mortality
Our study showed a five-year mortality rate of 55%. A recently 
published cohort study using data from 73,106 patients 
 hospitalized with COPD also showed high mortality of 50% 
and 75% at 3.6 and 7.7 years, respectively.46 Again, patient-
reported outcomes were not included.
The five-year mortality rate in the study by Soler-Cataluna 
et al3 was 38.2% after hospital admission for an exacerbation of 
COPD and 27% in the study by Nishimura.47 Patients in those 
studies were of approximately similar age, and had a higher 
FEV
1
 predicted (46.4% and 41.1%, respectively) compared with 
36.9% in our study. In the study by Nishimura, 33% were cur-
rent smokers versus 49% in the current study. Smoking status 
and more severe obstruction might explain the high mortality 
rate in the current study. Unfortunately, the patient-reported 
outcome measures were different in the Soler-Cataluna et al 
and Nishimura et al studies, so the health status level cannot 
be compared, but CCQ in the adjusted model was still shown 
to be able to predict mortality in our study.
Strengths and limitations
The strength of this study is that we could collect daily 
patient-reported outcomes in two well-controlled environ-
ments, resulting in few missing data. However, the hospital 
exacerbation study used data from a single-center study and 
patients with respiratory failure were not included. To some 
degree, this limits generalization of the data to more severe 
exacerbations. The outpatient study is small, and the avail-
able information is different, so there are concerns about 
the generalization of the results in this group, but the data 
are of high quality by design and add important information 
for the interpretation of results. Future studies are needed 
to confirm our findings and assess the predictive value of 
measurement of daily health status in a prospective algorithm 
in a broader group of patients. In the time to next exacerba-
tion analyses, the number of previous exacerbations was not 
significant, contrary to a report that exacerbation history is 
a strong predictor of future exacerbations.48 Unfortunately, 
we only had history of hospital admissions available, and 
not exacerbations treated at home, which might cause the 
signal in the univariate analysis (P = 0.101), but above our 
predefined threshold for inclusion in the models. Secondly, 
in our study, it was not possible to calculate the Charlson 
comorbidity index, so this was not included in our models, 
although comorbid diseases are predictors of worse outcome 
in exacerbations. Next, the currently widely promoted CAT 
test was not available at the time of these studies, so could 
not be included. A recently published study suggests that 
the CAT can be used to assess severity of exacerbations and 
shows higher baseline scores in frequent exacerbators49 as 
does the CCQ,42 but the responsiveness of CAT is difficult 
to interpret because its MCID is not yet known.
Conclusion
In conclusion, it is possible and feasible to perform daily 
 measurements of patient-reported outcomes even during 
inhospital exacerbations. The absence of improvement 
on the first day in the CCQ symptoms score (an easily 
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measured  variable even during an exacerbation) predicts 
treatment  failure. We suggest that patients who do show 
an improvement of 1 MCID in the CCQ (0.4) might be 
eligible for early  discharge, but this needs to be tested in a 
prospective algorithm. There is a marked difference in health 
status between patients treated at home or in hospital for an 
 exacerbation of COPD, while the rate of recovery of health 
status is similar. Health status as measured by the CCQ after 
an exacerbation of COPD predicts mortality and time to next 
exacerbation. Therefore, patient-reported outcomes could help 
decision-making in patients with an exacerbation of COPD.
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